Sun pharmaceuticals earned the highest revenue from its anti-diabetic drug formulation, Istamet, with a value of 2.5 billion Indian rupees in 2019. This was closely followed by their neuro and central nervous system drug formulation, Levipil, and cardiac formulation Rosuvas that year. Sun pharma was the leader in generic gynecological drug formulations in India with close to 1.8 billion rupees in 2019.
…. more: Statista.com (Quelle/Source)